Sign In
Home
Halaven - Eribulin Mesylate injection
Get your patient on
Halaven - Eribulin Mesylate injection
(Eribulin Mesylate)
injectable - 0.5 mg/ml injection 2 ml
Check coverage
See the specific documentation and step therapies required.
Check coverage
Medication interactions
See all drug-to-drug interactions for this medication.
Check interactions
Prescribing info
PubMed™ news
Halaven - Eribulin Mesylate injection prescribing information
Data source
Data source
Data Source
We receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available
Report Adverse Event
Check medication interactions
Review interactions as part of your prescribing workflow
Check interactions
Halaven - Eribulin Mesylate injection PubMed™ news
Last year
Publication date
Article Type
Format
5 articles
Reset Filters
5 most recent articles for Halaven - Eribulin Mesylate injection
,
view all articles on PubMed™
Journal Article • 2026 May
Outcomes for females versus males treated with eribulin mesylate for advanced urothelial carcinoma.
Journal Article • 2026 Mar
CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.
Journal Article • 2025 Aug
An open-label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2-negative metastatic breast cancer.
Journal Article • 2025 Jul
More Than Three Years of Hepatic Recurrence-Free Survival After Radiofrequency Ablation for Hepatic Metastasis From Triple-Negative Breast Cancer.
Journal Article • 2025 May
Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2-Year Post-Marketing Surveillance.
Show the latest PubMed™ articles for Halaven - Eribulin Mesylate injection
I certify that I'm a U.S. healthcare provider
